biotech analyst roundup StockInsight™ Biotech Analyst Roundup: 9 Biotech Stocks Facing Major Clinical Catalysts and Re-Rating Potential Editas Medicine (EDIT) — Hold Editas Medicine remains a Hold in the analyst view, with the investment case centered less on an established clinical pipeline and more on the potential reset created by EDIT-401. The key issue is that Editas currently has no…

This content is for subscribers only. Please click here to see our plans.

This content is for subscribers only. Please click here to see our plans.

biotech & health insights 🏥 HEALTH INDUSTRY NEWS 🚨 BREAKING HEALTH HEADLINES 🇺🇸 United States • A small clinical study found that psychedelic-assisted therapy significantly reduced symptoms of PTSD in military veterans, adding to growing evidence supporting psychedelic treatments for mental health disorders. • Drugmakers and major retailers face U.S. litigation over allegedly misleading “maximum strength” claims for oral decongestant…

This content is for subscribers only. Please click here to see our plans.